San Diego – Bahram Valamehr, President and CEO of Fate Therapeutics Inc. (NASDAQ:FATE), sold 28,946 shares of common stock on May 20, 2026, according to a filing with the SEC. The transactions totaled $54,482.
Shares were sold at prices ranging from $1.825 to $1.935 per share, with a weighted average price of $1.8822. The sales were executed to cover tax withholding obligations related to the vesting of 50,000 performance-based RSUs granted on July 29, 2024. These "sell-to-cover" transactions were automatic and not discretionary.
The stock now trades at $2.10, up from the previous close of $1.89. Year-to-date, the stock has surged 87%, with a 79% return over the past six months.
According to Bond.az analysis, the stock appears fairly valued at current levels. Following the sales, Mr. Valamehr directly holds 635,762 shares.
In recent news, Fate Therapeutics presented CAR T-cell therapy data at medical conferences. The FT819 therapy showed promising results in a Phase 1 study for systemic lupus erythematosus. Jefferies initiated coverage with a Buy rating and $4.00 target. H.C. Wainwright raised its target to $7, maintaining a Buy rating.
